ONL DRC A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients with Macula-off, Rhegmatogenous Retinal Detachment
Research Grant
Administered By
Ophthalmology
Awarded By
ONL Therapeutics
Start Date
September 20, 2019
End Date
December 31, 2022
Administered By
Ophthalmology
Awarded By
ONL Therapeutics
Start Date
September 20, 2019
End Date
December 31, 2022